Vision and Mission
Minimize the impact of pain on humanity by enabling fast, safe, and precise treatment for millions of patients through groundbreaking inhalation technology.
Redefining Pain Medicine
Syqe is a MedTech company transforming the future of pain management through precision inhaled therapeutics.
Our proprietary technology platform enables pharmaceutical-grade drug delivery with unparalleled accuracy, consistency, and safety redefining how chronic pain is treated.
Patients and healthcare professionals are already using Syqe’s technology, demonstrating measurable improvement in pain relief and quality of life.
In parallel, the company is conducting a global clinical trial to validate the therapeutic efficacy further and support regulatory expansion into additional markets.
By combining advanced engineering, clinical excellence, and patient-centered innovation, Syqe is setting a new global standard for precision pain medicine, measurable, scalable, and sustainable.
THE FUTURE OF MEDICINE
The safest and most precise drug inhalation technology
The Unmet Need: A Global Pain Crisis
Chronic pain is recognized by the World Health Organization (WHO) as one of the leading causes of long-term disability worldwide [1].
According to recent epidemiological data, over one billion people suffer from chronic pain, and more than 400 million experience moderates to severe pain on a daily basis [2].
Chronic pain is frequently accompanied by sleep disturbances, depression, and reduced cognitive function, deeply impacting quality of life and productivity [3].
Unlike acute pain, which serves as a physiological alarm system, chronic pain is maladaptive a pathological rewiring of the central nervous system.
Neuroscientific studies have shown that prolonged exposure to pain leads to central sensitization, a state where the spinal cord and brain amplify pain signalling, causing the sensation of pain even in the absence of actual tissue damage [4].
This process, often described as pain memory, transforms pain from a symptom into a chronic neurological condition.
Despite the wide availability of pharmacological treatments including opioids, anticonvulsants, and antidepressants most patients report inadequate or inconsistent relief.
Clinical studies indicate that over 60% of chronic pain patients discontinue their treatment within six months due to limited efficacy or side effects such as sedation, dependency, or gastrointestinal issues [5].
As a result, chronic pain remains a global medical and economic burden, costing an estimated $560–$635 billion annually in the United States alone more than heart disease, cancer, and diabetes combined [6].
This massive unmet need highlights the urgency for innovative, evidence-based solutions that provide effective, safe, and personalized pain relief.
Sources
Why Syqe
Since 2011 – Pioneering Innovation in Chronic Pain Treatment
For over a decade, Syqe has been redefining the standards of pain management through innovation, science, and real-world clinical impact.
Our metered-dose inhalation platform is the only one of its kind, enabling physicians to prescribe plant-based medicine with pharmaceutical precision, safety, and predictability.
Syqe’s technology has been clinically validated, demonstrating rapid onset of action, precise micro-dosing accuracy, and an exceptional safety profile across multiple studies and real-world settings.
With regulatory approvals including CE (Europe), ARTG (Australia), MDL (Canada), EU-GMP, and IMC-GMP, our platform meets the highest global pharmaceutical and manufacturing standards.
Operating commercially in Israel and Australia, Syqe has treated thousands of patients and built a unique Real-World Evidence (RWE) database that continuously supports clinical innovation and regulatory advancement.
Our commercial collaborations with the Israeli Ministry of Defense, National Insurance Institute, and the Australian Veterans Affairs reflect growing institutional trust in the safety, efficacy, and scalability of our solution.
Together, these achievements position Syqe at the forefront of precision inhalation medicine—transforming the way chronic pain is managed worldwide.
Clinical Progress in Europe
DPNP (Diabetic Peripheral Neuropathic Pain)
Preclinical
Phase 1
Phase 2
Phase 3
Filed for registration
PTSD (Post-Traumatic Stress Disorder)
Preclinical
Phase 1
Phase 2
Phase 3
Filed for registration
Lumbar Pain (Lower Back Pain)
Preclinical
Phase 1
Phase 2
Phase 3
Filed for registration
Insomnia
Preclinical
Phase 1
Phase 2
Phase 3
Filed for registration
Our Team
Founder & CEO, Syqe® Group Perry is the founder of Syqe® and serves as CEO of the company. Has over a decade of experience in the regulation of controlled substances and was previously the co-founder and CEO of the first Israeli cannabis company. Perry invented a number of patents in various fields, including Syqe®’s core technology. Perry strongly believes in Syqe®'s work and responsibility in reducing the pain and suffering of as many people as possible in the fastest possible way, using groun
Executive Medical Chairman Eytan brings to Syqe® his medical knowledge and extensive experience working with medical systems, medical staff and patients. previously served as the Director General of the Israeli Ministry of Health and Director General of Soroka University and Assuta Medical Centers. Also served as the Director of the Central District and Tel Aviv District of Clalit Health Services. Eytan is a family medicine specialist, graduate of the Ben-Gurion University of the Negev’s School
CFO & COO Ido is responsible for leading the company's financial and operational vision and strategies, including overseeing our Finance, Legal, IP, IT, Supply Chain, and Production Operations efforts. Ido has over 20 years of experience in financial management in global high-tech and manufacturing companies, including senior positions such as VP Finance & Strategy at Verint Systems (Nasdaq: VRNT), Director Corporate FP&A at Netafim, and VP Corporate Finance & Division CFO at Cellebrite. He also
CTO Roee oversees Pharmaceutical Engineering and Product Management at SyqePharma BU. In the past, he played a central role in product development and was responsible for establishing the company's production infrastructure and processes, including manufacturing tooling and automation. Currently, he leads key engineering efforts such as CMC, process engineering, knowledge transfer, and industrialization. Since joining Syqe® in 2012, Roee has held pivotal roles such as VP of Engineering and R&D T
VP QA & RA With over 20 years in the medical devices industry in senior roles of quality and regulatory affairs at Israeli and international companies such as J&J, Alere and West Pharma, Naama brings her professional knowledge in establishing and maintaining the compliance and effectiveness of Quality Management Systems as well as worldwide Regulatory Strategies for market penetration. Leveraging her rich professional experience, Naama successfully obtained the company’s first ISO13485 certifica
CEO, SyqeAir Hagit is in charge of the business and commercial development of the SyqeAir business unit at Syqe®, leading the product and clinical fields, marketing and advertising, and patient experience. Has extensive and diverse experience in interdisciplinary management in leading companies of large and medium scale, both in the private and public sectors, such as Paz Oil Company, Shufersal Finances, Radio eco99fm, and Ichilov Medical Center. Hagit managed complex departments and professiona
Business Operations Director Sharon is responsible for the development and management of all processes at Syqe®, with the aim of realizing the company's goals, while making the best use of all its internal organizational resources. In her previous role at Syqe®, managed cross-organizational strategic projects. Sharon brings to Syqe® over a decade of experience in managing diverse projects and leading complex processes in leading global high-tech companies. Sharon holds a BA in behavioral science
Co-Founder & CEO, SyqePharma Benny is one of the company founders who initially led the development of the product and production infrastructure. Currently, he leads and outlines the strategy for the business unit in charge of charting the company's Pharmaceutical Route. The unit deals with efforts in diverse fields, including Regulatory, Clinical, Chemistry, Manufacturing and Controls (CMC), Engineering and Industrialization, and Project and Product Management. Benny is one of the company's fir
Head of Legal Oren oversees all of Syqe®'s corporate legal affairs and serves as secretary of the organization. As part of his role in the company, he provides legal guidance to all company's activities, including fundraising, commercial negotiations, and drafting of agreements. Oren is an experienced lawyer with a demonstrated and diverse history of working in high-tech, biotechnology, medical device, phrama, and cannabis industries, both as an in-house legal counsel in technological companies
WE TURN SCIENCE INTO IMPACT
120
Employees
6
Core Team
200
Patents
100
Partners
We Care Deepl
We care about people. This defines us, and we stop at nothing in our journey to make people’s lives better
We Are Creators
We grow by envisioning, doing, and solving daring to push boundaries and create new realities
We Achieve Together
We have each other’s backs our openness and collaboration empower us to achieve more together
We Are Free to Be
To be our true selves, our differences inspire us and make Syqe an exciting, creative place to belong
Join us in redefining how medicine is delivered
At Syqe, we’re redefining how the world delivers and experiences medicine.
Our mission is to transform pain treatment through science, precision, and purpose — creating technology that empowers patients and elevates standards of care. We believe that compassion and engineering can coexist, designing solutions that give people control, dignity, and freedom from pain.
Join us in shaping the future of precision inhalation therapy where your talent truly makes a difference.